AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio
AbbVie said on Thursday it will buy drugmaker ImmunoGen for $10.1 billion, boosting its presence in the market
2023-11-30 20:54
AbbVie trims full-year profit forecast on higher R&D expenses
(Reuters) -AbbVie Inc cut its full-year profit forecast on Thursday, citing $280 million in milestone and in-process research and development
2023-07-07 05:20